Durect corporation to announce second quarter 2023 financial results and provide a business update

Cupertino, calif. , aug. 3, 2023 /prnewswire/ -- durect corporation (nasdaq: drrx), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program, today announced that the company will report its financial results for the three months ended june 30, 2023 on wednesday, august 9, 2023.
DRRX Ratings Summary
DRRX Quant Ranking